Pathomechanisms of nephrogenic systemic fibrosis: New insights

Clinical and Experimental Dermatology

Volumn 36, Issue 7, 2011, Pages 763-768

  Gupta, A ^a   Shamseddin, M K ^a   Khaira, A ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Moolchand Hospital   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DECORIN; GADOLINIUM; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; METALLOTHIONEIN; OSTEOPONTIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; VERSICAN;

HUMAN; KIDNEY FAILURE; MACROPHAGE; MYOFIBROBLAST; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INDUCTION; REVIEW;

CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY;

EID: 80052961268     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2011.04136.x     Document Type: Review

References (23)

1. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000-1.
2. Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001; 23: 383-93. (Pubitemid 32938907)
3. Ting WW, Stone MS, Madison KC, Kurtz K,. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003; 139: 903-6. (Pubitemid 36898926)
4. Cowper SE,. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 2005; 46: 763-5. (Pubitemid 41383957)
5. Grobner T,. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104-8.
6. US Food and Drug Administration Center for Drug Evaluation and Research. Transcript of Joint Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committees meeting, 8 December 2009. RenalDrugsAdvisoryCommittee/UCM197768.pdf (accessed 15 February 2011).
7. Swaminathan S, Shah SV,. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 2007; 18: 2636-43. (Pubitemid 47531189)
8. Kuo PH,. NSF-active and NSF-inert species of gadolinium: mechanistic and clinical implications. Am J Roentgenol 2008; 191: 1861-3.
9. Bucala R,. Impact of GBCA on fibrocyte function. X-ray analysis demonstrates phosphate-bound Gd in skin in nephrogenic systemic fibrosis. Presented at the Fourth Annual Symposium on Nephrogenic Systemic Fibrosis and Gadolinium-based Contrast Agents. 14-15 May 2010. New York, NY: NY Academy of Sciences, 2010.
10. Swartz RD, Crofford LJ, Phan SH, et al. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 2003; 114: 563-72. (Pubitemid 36577259)
11. Edward M, Quinn JA, Mukherjee S, et al. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 2008; 214: 584-93. (Pubitemid 351482273)
12. Edward M, Jardine A, Quinn J, et al. Effect of gadolinium-based contrast agents on fibroblasts: a possible link to nephrogenic systemic fibrosis. Presented at the Fourth Annual Symposium on Nephrogenic Systemic Fibrosis and Gadolinium-based Contrast Agents. 14-15 May 2010. New York, NY: NY Academy of Sciences, 2010.
13. Piera-Velazquez S, Louneva N, Fertala J, et al. Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. Ann Rheum Dis 2010; 69: 2017-23.
14. Nicholas SB,. The role of osteopontin in fibrosis. Presented at the Fourth Annual Symposium on Nephrogenic Systemic Fibrosis and Gadolinium-based Contrast Agents. 14-15 May 2010. New York, NY: NY Academy of Sciences, 2010.
15. Idée JM, Port M, Medina C, et al. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology 2008; 248: 77-88.
16. Steger-Hartmann T, Raschke M, Riefke B, et al. The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis-a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. Exp Toxicol Pathol 2009; 61: 537-52.
17. Kelly BC, Markle LS, Vickers JL, et al. The imbalanced expression of matrix metalloproteinases in nephrogenic systemic fibrosis. J Am Acad Dermatol 2010; 63: 483-9.
18. Jiménez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004; 50: 2660-6. (Pubitemid 39062729)
19. Nagarajan RP, Chen F, Li W, et al. Repression of transforming-growth- factor-beta-mediated transcription by nuclear factor kappaB. Biochem J 2000; 348: 591-6. (Pubitemid 30410249)
20. Del GaldoF, Wermuth PJ, Addya S, et al. NFκB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. Ann Rheum Dis 2010; 69: 2024-33.
21. Gambichler T, Kreuter A, Skrygan M, et al. Decorin is significantly overexpressed in nephrogenic systemic fibrosis. Am J Clin Pathol 2009; 132: 139-43.
22. High WA, Ayers RA, Cowper SE,. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56: 710-12. (Pubitemid 46400200)
23. Kreuter A, Höxtermann S, Gambichler T, et al. Detection of clonal T cells in the circulation of patients with nephrogenic systemic fibrosis. Arch Dermatol 2009; 145: 1164-9.